

FDA Approved CDx	Tumor Type	Scoring Method	FDA Approved Therapy
PD-L1 IHC 22C3	Non-Small Cell Lung Cancer (NSCLC)	Tumor Proportion Score (TPS)	Keytruda® (pembrolizumab)
	Gastric or Gastroesophageal Junction (GEJ) adenocarcinoma	Combined Positive Score (CPS)	Keytruda® (pembrolizumab)
	Cervical Cancer	Combined Positive Score (CPS)	Keytruda® (pembrolizumab)
	Urothelial Carcinoma (URC)	Combined Positive Score (CPS)	Keytruda® (pembrolizumab)
	Head and Neck Squamous Cell Carcinoma (HNSCC)	Combined Positive Score (CPS)	Keytruda® (pembrolizumab)
	Esophageal Squamous Cell Carcinoma (ESCC)	Combined Positive Score (CPS)	Keytruda® (pembrolizumab)
PD-L1 IHC SP142	Urothelial Carcinoma (URC)	Tumor Cell (TC) Score (%) Tumor-Infiltrating Immune Cell (IC) Score (%)	Tecentriq® (atezolizumab)
	Triple Negative Breast Cancer (TNBC)	Tumor-Infiltrating Immune Cell (IC) Score (%)	Tecentriq® (atezolizumab)